NCT03666936 is a NA clinical trial of Social-health care intervention in Neoplasms, sponsored by Azienda USL Reggio Emilia - IRCCS.

Who is sponsoring NCT03666936?

NCT03666936 is sponsored by Azienda USL Reggio Emilia - IRCCS.

What drugs are being tested in NCT03666936?

Interventions in NCT03666936: Social-health care intervention.

What condition does NCT03666936 study?

NCT03666936 studies Neoplasms, Return to Work.

Is NCT03666936 still recruiting?

NCT03666936 is currently completed. Last updated 13 June 2025.

Last reviewed 2025-06-13 · How we verify

NCT03666936

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Facilitate the Return to Work of Cancer Survivors

Completed NA Last updated 13 June 2025

What this trial tests

NA trial testing Social-health care intervention in Neoplasms in 34 participants. Completed in 31 January 2021.

Timeline

1 May 2018

Primary endpoint
31 January 2020

31 January 2021

Quick facts

Lead sponsor	Azienda USL Reggio Emilia - IRCCS
Phase	NA
Status	Completed
Study type	INTERVENTIONAL
Allocation	na
Design	single group
Masking	none
Primary purpose	treatment
Enrollment	34
Start date	1 May 2018
Primary completion	31 January 2020
Estimated completion	31 January 2021
Sites	1 location across Italy

Drugs / interventions tested

Social-health care intervention

Conditions studied

Neoplasms — all drugs for Neoplasms →
Return to Work — all drugs for Return to Work →

Sponsor

Azienda USL Reggio Emilia - IRCCS — full company profile →

Who can join

Eligibility, any sex, with Neoplasms or Return to Work. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

Cancer patients could experience physical limitations, cognitive symptoms, fatigue and pain, that could be perceived at diagnosis but may also occur during treatment, limiting the person from carrying out their activities of daily living, including work tasks. Return to work is a major goal, as it facilitates the patient's ability to deal with the disease and improve general health. At present, there is no path aimed at supporting cancer patients in the return to work process. Because of this, the investigators want to assess the feasibility of a multidisciplinary social-health care pathway aimed at manage the difficulties that cancer patients might perceive in the return to work process.

Publications & conference data

2 peer-reviewed publications reference this trial (live from Europe PMC):

Non-medical interventions to enhance return to work for people with cancer.
de Boer AG, Tamminga SJ, Boschman JS, Hoving JL. · · 2024 · cited 21× · PMID 38441440 · DOI 10.1002/14651858.cd007569.pub4
A social-healthcare pathway to facilitate return to work of cancer survivors in Italy: The UNAMANO project.
Paltrinieri S, Ricchi E, Mazzini E, Cervi E, et al · · 2021 · cited 5× · PMID 34842210 · DOI 10.3233/wor-205249

Verify or expand the search:

Other recruiting trials for Neoplasms

Currently open trials in the same condition.

NCT07438782 — First Time in Human (FTIH) Study to Investigate the Safety and Preliminary Activity of GSK5533524 Alone or in Combinatio · Phase 1 · recruiting
NCT07382817 — Phase 1 Study of JV-394 Autologous Anti-CD94 CAR T for r/r CD94+ T/NK Cell Neoplasms · Phase 1 · recruiting
NCT07277270 — A Study of GSK5764227 in Combination With Standard of Care (SoC) or Other Agents in Participants With Advanced Solid Tum · Phase 1 · recruiting
NCT07257640 — IL-5 CAR-T Cell Therapy for Refractory/Relapsed Eosinophilic Leukemia · Phase 1 · recruiting
NCT07213609 — A Study to Investigate the Safety and Preliminary Efficacy of GSK5460025 Alone or in Combination With Other Anti-cancer · Phase 1, PHASE2 · recruiting

Other Azienda USL Reggio Emilia - IRCCS trials

Trials by the same sponsor.

NCT07373626 — Physical Activity Trends in Cancer Survivors Treated at the 'MOvement and REhabilitation' Clinic · recruiting
NCT07000162 — LAttice Radiation Therapy for Large Lesions: Reggio Emilia Single-arm Phase II Trial · Phase 2 · recruiting
NCT06629896 — Contrast Enhancement Mammography vs MRI for the Surveillance of Women at High Risk of Breast Cancer: Con-trust Randomize · NA · recruiting
NCT06749600 — Clinical Management and Outcomes of Primary Ovarian Leiomyosarcoma · recruiting
NCT06624280 — Does Orthopedic Surgery Improve Gait Efficiency in Children With Cerebral Palsy? A Retrospective Study · completed

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT03666936 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Azienda USL Reggio Emilia - IRCCS
Last refreshed: 13 June 2025

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03666936.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing